Clinical Trial Update: Dose-response Study of Exendin-9,39 on Glucose Metabolism [Phase 1]

View source ↗

Summary

Phase 1 dose-response study evaluating the effects of Exendin-(9-39) and GLP-1(9-36) on glucose metabolism and pancreatic function; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• Exendin 9-39 (exendin-9-39)
• GLP-1(9-36) (GLP-1(9-36))

Snippet

Sponsor: Adrian Vella | Conditions: Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1 | Phase 1 | Status: COMPLETED